Trial Profile
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab
- Indications Alveolar soft part sarcoma
- Focus Therapeutic Use
- 12 Oct 2023 Planned End Date changed from 31 Oct 2023 to 31 Oct 2025.
- 12 Oct 2023 Planned primary completion date changed from 31 Oct 2023 to 31 Oct 2025.
- 07 Sep 2023 Results (n=52) published in the New England Journal of Medicine